Skip to main content
Contact Us
Subscribe
E-Edition
54°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vbi Vaccines Inc CS
(NQ:
VBIV
)
0.0653
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Aug 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Vbi Vaccines Inc CS
< Previous
1
2
3
4
Next >
VBI Vaccines Provides an Update on its Restructuring Proceedings
August 02, 2024
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives
July 30, 2024
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Results of Annual General Meeting
June 25, 2024
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients
May 29, 2024
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients
May 22, 2024
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Reports First Quarter 2024 Financial Results
May 15, 2024
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Reports Full Year 2023 Financial Results
April 16, 2024
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
April 11, 2024
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
April 09, 2024
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
April 03, 2024
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
April 02, 2024
From
VBI Vaccines Inc.
Via
Business Wire
VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences
February 14, 2024
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting
November 20, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Reports Third Quarter 2023 Financial Results
November 14, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program
October 26, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern
September 27, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM
September 07, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis B
September 06, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Reports Second Quarter 2023 Financial Results
August 14, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Closing of Underwriters’ Partial Exercise of Option to Purchase Additional Common Shares
July 24, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults
July 19, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Pricing of $18 Million Public Offering and $3 Million Concurrent Registered Direct Offering
July 06, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares and Warrants
July 05, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership To Address Both Prevention and Treatment in License and Collaboration Agreements for up to $437 Million Plus Royalties
July 05, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Results of Annual General Meeting
June 23, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces PreHevbri® is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults
June 15, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Poster Presentation at EASL 2023
June 07, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Reports First Quarter 2023 Financial Results
May 15, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Appoints Vaughn Himes to Board of Directors
April 25, 2023
From
VBI Vaccines Inc.
Via
Business Wire
VBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock Split
April 04, 2023
From
VBI Vaccines Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.